Design, Synthesis, and Mechanistic Anticancer Evaluation of New Pyrimidine-Tethered Compounds
Pharmaceuticals · 19.02.2025 · 18 (2) · 270
DOI: 10.3390/ph18020270 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 19.02.2025. Verfasst von Farida Reymova und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering Sciences, Izmir Katip Celebi University, Izmir 35620, Türkiye. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific and Technological Research Council of Turkey.
Abstract (Originalsprache)
Background
Despite recent breakthroughs in cancer treatment, non-small cell lung cancer (NSCLC) and breast cancer remain major causes of death from all malignancies. The epidermal growth factor receptor (EGFR) is an important mediator of the pathways involved in cell proliferation, apoptosis, and angiogenesis. Thus, its overexpression triggers several types of cancer, including NSCLC and breast cancer.
Methods
In the current study, we synthesized new pyrimidine-tethered compounds (chalcone derivative (B-4), pyrazoline–carbothioamide (B-9), and pyrazoline–thiazole hybrids (BH1-7)). These compounds were then tested for cytotoxicity against A549 NSCLC and MCF-7 breast cancer cells.
Results
Of these, B-4 displayed significant cytotoxicity against both cells (IC50 = 6.70 ± 1.02 µM for MCF-7; IC50 = 20.49 ± 2.7 µM for A549) compared to the standard agent lapatinib (IC50 = 9.71 ± 1.12 µM for MCF-7; IC50 = 18.21 ± 3.25 µM for A549). The anticancer potential of B-4 between Jurkat leukemic T cells and peripheral blood mononuclear cells (PBMCs) (healthy) was found to be selective. Mechanistically, 11.9% and 10.2% of A549 and MCF-7 cells treated with B-4, respectively, underwent apoptosis and B-4 produced 46% EGFR inhibition at a concentration of 10 μM. The B-4/EGFR complex obtained after induced fit docking was subjected to 300 ns of molecular dynamics simulation, which confirmed the stability of the complex in a mimicked biological environment. On the other hand, B-4 was shown to have drug-like properties by in silico pharmacokinetic estimation.
Conclusions
B-4 is an EGFR inhibitor and apoptosis inducer for future NSCLC and breast cancer studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Bioengineering Sciences, Izmir Katip Celebi University, Izmir 35620, Türkiye.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskisehir 26470, Türkiye.
- Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, Japan.
- Department of Molecular Biology and Genetics, Koc University, Istanbul 34450, Türkiye.
- Department of Basic Pharmaceutical Sciences, Faculty of Pharmacy, Izmir Katip Celebi University, Izmir 35620, Türkiye.
- Department of Chemistry, Faculty of Science, Istanbul University, Fatih, Istanbul 34126, Türkiye.
ORCID-Profile: Belgin Sever, Canan Sevimli-Gur, Mustafa Can, Amaç Fatih Tuyun, Faika Başoğlu, Abdulilah Ece, Mikako Fujita, Hasan Demirci, Halilibrahim Ciftci
Förderung
- Scientific and Technological Research Council of Turkey
Zitieren
APA
Reymova, F., Sever, B., Topalan, E., Sevimli-Gur, C., Can, M., Tuyun, A. F., Başoğlu, F., Ece, A., Otsuka, M., Fujita, M., Demirci, H., & Ciftci, H. (2025). Design, Synthesis, and Mechanistic Anticancer Evaluation of New Pyrimidine-Tethered Compounds. Pharmaceuticals, 18(2), 270. https://doi.org/10.3390/ph18020270
Vancouver
Reymova F, Sever B, Topalan E, Sevimli-Gur C, Can M, Tuyun AF, et al. Design, Synthesis, and Mechanistic Anticancer Evaluation of New Pyrimidine-Tethered Compounds. Pharmaceuticals. 2025;18(2):270. doi:10.3390/ph18020270
BibTeX
@article{Reymova2025,
author = {Reymova, Farida and Sever, Belgin and Topalan, Edanur and Sevimli-Gur, Canan and Can, Mustafa and Tuyun, Amaç Fatih and Başoğlu, Faika and Ece, Abdulilah and Otsuka, Masami and Fujita, Mikako and Demirci, Hasan and Ciftci, Halilibrahim},
title = {Design, Synthesis, and Mechanistic Anticancer Evaluation of New Pyrimidine-Tethered Compounds},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {2},
pages = {270},
doi = {10.3390/ph18020270}
}
EUVIMED